DISCLAIMER

The Diabetes Québec Toolbox is intended for Québec healthcare professionals only. By accessing this web application, you confirm that you are a healthcare professional. The information in the Toolbox is provided for general information purposes only and is not comprehensive. Under no circumstances can Diabetes Québec be held responsible for any error or omission or be prosecuted for any reason whatsoever.

Classes
Oral and Non Insulin Agents

BIGUANIDES
Oral medications

Metformin
Glucophage®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550 mg
Covered
Characteristics and clinical considerations
Product Monograph

Metformin ER
Glumetza®
500 mg - 1000 mg
OD
Maximum daily dose: 2000 mg
Not covered / Private coverage
Characteristics and clinical considerations
Product Monograph

ALPHA-GLUCOSIDASE INHIBITOR
Oral medications

Acarbose
GlucobayTM
50 mg - 100 mg
OD to TID
Maximum daily dose: 300 mg
Covered
How to initiate
Characteristics and clinical considerations
Product Monograph

DPP-4 INHIBITORS
Oral medications

Alogliptin and Metformin
KazanoTM
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Linagliptin and Metformin
JentaduetoTM
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Saxagliptin and Metformin
Komboglyze®
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Sitagliptin and Metformin
Janumet®
50 mg/500 mg - 50 mg/850 mg - 50 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Sitagliptin and Metformin ER
Janumet® XR
50 mg/500 mg - 50 mg/1000 mg - 100 mg/1000 mg
OD
Code EN150
Characteristics and clinical considerations
Product Monograph

Canaglifozin and Metformin
Invokamet®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Empagliflozin and Linagliptin
Glyxambi®
10 mg/ 5 mg - 25 mg/5 mg
OD
Not covered / Private coverage
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Empagliflozine and Metformin
SynjardyTM
5 mg/500 mg - 5/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN219
Product Monograph
Cardio-renal protection clinical data
Characteristics and clinical considerations

INSULIN SECRETAGOGUES
Oral medications

Gliclazide
Diamicron®
80 mg
OD to BID
Maximum daily dose: 320 mg
Covered
Characteristics and clinical considerations
Product Monograph

Gliclazide Modified Release
Diamicron®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Covered
Characteristics and clinical considerations
Product Monograph

Glimepiride
Amaryl®
1 mg - 2 mg - 4 mg
OD to BID
Maximum daily dose: 8 mg
Code EN23
Characteristics and clinical considerations
Product Monograph

Glyburide
Diabeta®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Covered
Characteristics and clinical considerations
Product Monograph

Repaglinide
GlucoNorm®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Covered
Characteristics and clinical considerations
Product Monograph

THIAZOLIDINEDIONES (TZD)
Oral medications
GLP-1R AGONISTS and GIP
Injectable medications s/c

Tirzepatide
MounjaroMC
2.5 mg - 5 mg - 7.5 mg - 10 mg - 12.5 mg - 15 mg (0.5 ml per vial, single-dose vial)
Once-Weekly
Stability at room temperature : 21 days
Private coverage
Complet Web Site
Instruction for use
Patient Brochure
Injection Training Video
Product Monograph

GLP-1R AGONISTS
Injectable medications s/c

Dulaglutide
Trulicity®
0.75 mg - 1.5 mg
(3.5 and 4.5 mg not yet available for purchase in Canada )
Once-Weekly
Stability at room temperature : 14 days
Private coverage orRAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Instructions for Use - Video
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Liraglutide
Victoza®
0.6 mg - 1.2 mg - 1.8 mg
OD
Stability at room temperature : 30 days
Private coverage or RAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Video demo. of the injection technic
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Lixisenatide
AdlyxineTM
10 ug/dose (0.05 mg/ml)
20 ug/dose (0.1 mg/ml)
OD
Stability at room temperature : 14 days
Not covered / Private coverage
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Semaglutide (s/c)
WegovyTM Obesity (≧ 30 BMI) et DB2 (≧ 27 BMI)
0.25 mg - 0.5 mg - 1 mg - 1.7 mg - 2.4 mg (Approved in Canada but not yet available for purchase)
Once-Weekly
Conservation : 8 weeks
Private coverage (when available)
Product Monograph

Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
SoliquaTM
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
Not Covered / Private coverage
How to Inject (video)
How to Inject (pdf)
Therapy Initiation and Titration
Cardio-renal protection clinical data
Characteristics and clinical considerations Product Monograph

Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Not Covered / Private coverage
Therapy Initiation and Titration
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph